Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.54B P/E 21.19 EPS this Y 3.10% Ern Qtrly Grth -0.20%
Income 474.62M Forward P/E 17.18 EPS next Y 12.80% 50D Avg Chg -
Sales 4.13B PEG 2.63 EPS past 5Y 14.18% 200D Avg Chg -4.00%
Dividend N/A Price/Book 3.39 EPS next 5Y 9.19% 52W High Chg -21.00%
Recommedations 2.10 Quick Ratio 1.00 Shares Outstanding 51.35M 52W Low Chg 14.00%
Insider Own 1.05% ROA 5.19% Shares Float 50.72M Beta 1.39
Inst Own 103.07% ROE 14.38% Shares Shorted/Prior 1.59M/1.92M Price 206.01
Gross Margin 37.03% Profit Margin 11.49% Avg. Volume 483,998 Target Price 266.34
Oper. Margin 14.52% Earnings Date May 9 Volume 373,835 Change -1.58%
About Charles River Laboratories Inte

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories Inte News
03/27/24 Charles River Laboratories Publishes 2023 Corporate Citizenship Report
03/26/24 Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
03/23/24 U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies
03/21/24 Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
03/15/24 Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
03/15/24 Charles River (CRL) Extends Gene Therapy Offering With New Pact
03/14/24 Here's Why You Should Retain Charles River (CRL) Stock Now
03/14/24 Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
03/12/24 Charles River Laboratories to Present at Barclays Global Healthcare Conference
03/11/24 Insider Sell: CSVP & Chief Accounting Officer Michael Knell Sells Shares of Charles River ...
03/07/24 Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
03/07/24 The Top 3 Healthcare Stocks to Buy in March 2024
03/01/24 Insider Sell: EVP & Chief People Officer Victoria Creamer Sells 5,000 Shares of Charles ...
02:00 AM Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
02/26/24 Charles River (CRL) Forges Collaboration With Wheeler Bio
02/22/24 Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
02/21/24 Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
02/21/24 Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
02/20/24 Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
02/16/24 Charles River Laboratories International Full Year 2023 Earnings: EPS Beats Expectations
CRL Chatroom

User Image 50bps Posted - 18 hours ago

$CRL 👀

User Image Stock_Titan Posted - 2 days ago

$CRL Charles River Laboratories Publishes 2023 Corporate Citizenship Report https://www.stocktitan.net/news/CRL/charles-river-laboratories-publishes-2023-corporate-citizenship-daukdsct3wca.html

User Image Nelsin Posted - 2 days ago

$CRL Buy to Open. Target: $290.84

User Image Stock_Titan Posted - 1 week ago

$CRL Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine https://www.stocktitan.net/news/CRL/charles-river-announces-extension-of-gene-therapy-manufacturing-lcbrog6an5nx.html

User Image erevnon Posted - 1 week ago

Argus Research maintains Charles River $CRL at Buy and raises the price target from $200 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Stock_Titan Posted - 2 weeks ago

$CRL Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration https://www.stocktitan.net/news/CRL/charles-river-and-navega-therapeutics-announce-comprehensive-gene-9ck9k4tts1z9.html

User Image InsiderPeek Posted - 2 weeks ago

$CRL Chief Accounting Officer Knell Michael Gunnar sold 808 shares for $216.2k (ownership down 10.32%) insiderpeek.com/company/CRL

User Image Stock_Titan Posted - 2 weeks ago

$CRL Charles River Laboratories to Present at Barclays Global Healthcare Conference https://www.stocktitan.net/news/CRL/charles-river-laboratories-to-present-at-barclays-global-healthcare-egpufgxsney0.html

User Image StockInvest_us Posted - 2 weeks ago

Signal alert: $CRL - Overbought Trend Short (Overvalued) https://stockinvest.us/l/XoX4imBFyP

User Image StockInvest_us Posted - 3 weeks ago

Signal alert: $CRL - Overbought Trend Short (Overvalued) https://stockinvest.us/l/57BijoGAZw

User Image CDMO Posted - 3 weeks ago

$CRL pumping non stop

User Image DonCorleone77 Posted - 1 month ago

$CRL Charles River enters pact with Wheeler Bio for Portable CMC platform Wheeler Bio announced a new strategic agreement with Charles River to offer Wheeler Bio's Portable CMC platform to Charles River Laboratory clients. The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.

User Image Stock_Titan Posted - 1 month ago

$CRL Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use https://www.stocktitan.net/news/CRL/wheeler-bio-seals-agreement-with-charles-river-to-offer-portable-cmc-kbtro855f4fs.html

User Image Yaloo159 Posted - 1 month ago

Bearish Alert for $CRL CHARLES RIVER LABORATORIES Potential Swing: 1.55%

User Image framus_morrigan Posted - 1 month ago

$CRL Monthly chart, log scale. On watch @triskis

User Image AnchorsAweigh Posted - 1 month ago

$CRL looks ready. Already got the move on $ICLR

User Image swingingtech Posted - 1 month ago

$CRL https://wallstreetwaves.com/interesting-crl-put-and-call-options-for-january-2025/

User Image Stock_Titan Posted - 1 month ago

$CRL Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing https://www.stocktitan.net/news/CRL/charles-river-and-wheeler-bio-complete-agreement-to-accelerate-the-pi1mxvfpwo52.html

User Image Stock_Titan Posted - 1 month ago

$CRL Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells https://www.stocktitan.net/news/CRL/charles-river-collaborates-with-pluristyx-expanding-its-portfolio-of-xx9uqe8zqvzq.html

User Image FlynancialAnalyst Posted - 1 month ago

$CRL $12.60B mc $XLV name going #StageTwo after holding key $200 level and 40 wk SMA to the penny a few weeks ago. 80 wk SMA turning up Fully institutionally owned, they have been steadily accumulating over the past 2 years, despite the shares getting cut in half

User Image swingingtech Posted - 1 month ago

$JNJ, $CRL, $CLPT, $EVO https://wallstreetwaves.com/the-next-johnson-johnson-3-healthcare-stocks-that-investors-shouldnt-ignore/

User Image AnchorsAweigh Posted - 1 month ago

@Doozio wow this entire sector is going. Check out $CRL $ICLR $MEDP (extended)

User Image Doozio Posted - 1 month ago

$CRL like an Oct/nov bahhhtom that leads to 🧠⏰

User Image swingingtech Posted - 1 month ago

$CRL https://wallstreetwaves.com/charles-river-laboratories-stock-surges-on-upbeat-annual-outlook-but-this-analyst-is-concerned/

User Image CDMO Posted - 1 month ago

$CRL awesome

User Image swingingtech Posted - 1 month ago

$CRL $LYFT $HCSG $RIOT https://wallstreetwaves.com/charles-river-laboratories-international-posts-upbeat-results-joins-robinhood-zillow-tow

User Image RichSaunder Posted - 1 month ago

$CLPT $CRL Charles River with a nice beat. They partner with CLPT. Nice look through on sector.

User Image Lights1980 Posted - 1 month ago

$CRL well although it wasn’t quite as high as I had hoped for the EPS, they still beat on both and have a great outlook for the year!!!!

User Image DonCorleone77 Posted - 1 month ago

$CRL Charles River sees FY24 EPS $10.90-$11.40, consensus $11.37 Sees FY24 revenue up 1%-4%, consensus $4.23B. The company said, "The Company is providing financial guidance for 2024. The 2024 revenue growth outlook reflects a continuation of the more cautious biopharmaceutical demand environment that the Company experienced throughout most of 2023. Earnings per share in 2024 are expected to benefit from higher revenue and modest operating margin improvement, as well as the acquisition of Noveprim, which is expected to contribute to the non-GAAP operating margin and at least $0.30 to non-GAAP earnings per share in 2024."

User Image DonCorleone77 Posted - 1 month ago

$CRL Charles River reports Q4 EPS $2.46, consensus $2.40 Reports Q4 revenue $1.01B, consensus $991.25M. James Foster, chairman, president and CEO, said, "Our 2023 performance demonstrated the resilience and stability of our strategy and business model. Despite moderating demand trends in the broader life sciences sector, we were able to deliver solid revenue growth and non-GAAP earning per share that were in the upper half of our original guidance ranges. We are focused on innovation, enhancing our portfolio to support clients from target discovery to non-clinical development, and delivering flexible solutions to respond to a changing industry and client requirements. As a result, Charles River is positioned exceptionally well to meet the evolving needs of our clients."

Analyst Ratings
Argus Research Buy Mar 18, 24
Evercore ISI Group Outperform Feb 15, 24
UBS Buy Feb 15, 24
Citigroup Neutral Feb 15, 24
Baird Outperform Feb 15, 24
JP Morgan Overweight Feb 15, 24
Guggenheim Neutral Feb 15, 24
JP Morgan Overweight Dec 20, 23
Citigroup Neutral Dec 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Girshick Birgit Corporate Executive.. Corporate Executive VP & COO Jan 10 Option 144.67 5,916 855,868 50,365 01/31/24
FOSTER JAMES C Chairman, President.. Chairman, President and CEO Jan 29 Option 144.67 17,436 2,522,466 227,827 01/31/24
LaPlume Joseph W EVP, Corp Strategy &.. EVP, Corp Strategy & Develop May 15 Sell 190.39 345 65,685 24,026 05/16/23
LaPlume Joseph W EVP, Corp Strategy &.. EVP, Corp Strategy & Develop May 12 Sell 193.55 959 185,614 24,371 05/15/23
MASSARO GEORGE Director Director May 11 Sell 193.43 288 55,708 4,964 05/15/23
Parisotto Shannon M CEVP, Disc & Safety.. CEVP, Disc & Safety Assessment Feb 16 Sell 252.49 4,558 1,150,849 6,010 02/21/23
Parisotto Shannon M CEVP, Disc & Safety.. CEVP, Disc & Safety Assessment Feb 16 Option 109.34 4,558 498,372 10,568 02/21/23
Girshick Birgit Corporate Executive.. Corporate Executive VP & COO Feb 16 Sell 251.9 3,205 807,340 41,038 02/17/23
Girshick Birgit Corporate Executive.. Corporate Executive VP & COO Feb 16 Option 109.34 3,205 350,435 44,243 02/17/23
LaPlume Joseph W EVP, Corp Strategy &.. EVP, Corp Strategy & Develop Nov 04 Sell 216.36 534 115,536 20,232 11/07/22
LaPlume Joseph W EVP, Corp Strategy &.. EVP, Corp Strategy & Develop Jul 06 Sell 226.13 200 45,226 20,766 08/08/22
LaPlume Joseph W EVP, Corp Strategy &.. EVP, Corp Strategy & Develop Feb 23 Sell 292.75 395 115,636 19,852 02/24/22
FOSTER JAMES C Chairman, President.. Chairman, President and CEO Feb 22 Option 144.67 17,436 2,522,466 234,228 02/23/22
FOSTER JAMES C Chairman, President.. Chairman, President and CEO Feb 22 Sell 289.37 17,436 5,045,455 216,792 02/23/22
Girshick Birgit Corporate Executive.. Corporate Executive VP Sep 15 Sell 441.61 2,425 1,070,904 27,602 09/15/21
MASSARO GEORGE Director Director Sep 01 Sell 442.57 2,539 1,123,685 4,855 09/01/21
MASSARO GEORGE Director Director Sep 01 Option 164.24 2,539 417,005 7,394 09/01/21
Creamer Victoria L EVP & Chief People O.. EVP & Chief People Officer Aug 17 Sell 415.24 6,917 2,872,215 6,386 08/17/21
Creamer Victoria L EVP & Chief People O.. EVP & Chief People Officer Aug 17 Option 149.49 6,917 1,034,022 13,303 08/17/21
Knell Michael Gunnar CSVP&Chief Accountin.. CSVP&Chief Accounting Officer Jun 07 Option 144.56 1,527 220,743 5,757 06/07/21
FOSTER JAMES C Chairman, President.. Chairman, President and CEO May 10 Sell 343.64 7,500 2,577,300 216,072 05/10/21
FOSTER JAMES C Chairman, President.. Chairman, President and CEO Feb 25 Option 88.05 24,009 2,113,992 245,160 02/25/21
FOSTER JAMES C Chairman, President.. Chairman, President and CEO Feb 25 Sell 284.46 24,009 6,829,600 221,151 02/25/21
Girshick Birgit Corporate Executive.. Corporate Executive VP Feb 23 Option 73.7 1,675 123,448 31,680 02/23/21
Girshick Birgit Corporate Executive.. Corporate Executive VP Feb 23 Sell 293.92 1,675 492,316 30,005 02/23/21